World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
96
Citations
39747
World Ranking
9554
National Ranking
290

Research.com Recognitions

  • 2013 - Fellow of the Royal Society of New Zealand

Overview

Andrew W. Roberts is affiliated with the Walter and Eliza Hall Institute of Medical Research in Australia. Their research spans medicine and biochemistry, genetics, and molecular biology, with significant contributions in genetics, hematology, molecular biology, pathology and forensic medicine, and oncology.

The scientist's work focuses on several main topics, including:

  • Chronic Lymphocytic Leukemia Research
  • Acute Myeloid Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Chronic Myeloid Leukemia Treatments
  • Protein Degradation and Inhibitors
  • Cancer Genomics and Diagnostics
  • Acute Lymphoblastic Leukemia research

Frequent publication venues for their work include:

  • Blood
  • Blood Advances
  • bioRxiv (Cold Spring Harbor Laboratory)
  • HemaSphere
  • Journal of Clinical Oncology

Selected recent papers authored or co-authored by Andrew W. Roberts include:

  • "Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML," 2020, Blood
  • "Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing," 2021, Genome biology
  • "Targeting MCL-1 in hematologic malignancies: Rationale and progress," 2020, Blood Reviews
  • "Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy," 2020, Journal of Clinical Oncology
  • "BCL2 and MCL1 inhibitors for hematologic malignancies," 2021, Blood

Frequent co-authors collaborating with Andrew W. Roberts include:

  • Andrew H. Wei
  • Mary Ann Anderson
  • John F. Seymour
  • David C.S. Huang
  • Constantine S. Tam

Throughout their career, Andrew W. Roberts has been recognized as a Fellow of the Royal Society of New Zealand, awarded in 2013.

Best Publications

  • ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

    Andrew J Souers;Joel D Leverson;Erwin R Boghaert;Scott L Ackler

  • Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Andrew W. Roberts;Matthew S. Davids;John M. Pagel;Brad S. Kahl

  • The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

    Mark F. van Delft;Andrew H. Wei;Kylie D. Mason;Kylie D. Mason;Cassandra J. Vandenberg

  • Programmed Anuclear Cell Death Delimits Platelet Life Span

    Kylie D Mason;Marina Carpinelli;Jamie I Fletcher;Janelle Elyse Collinge

  • SOCS3 negatively regulates IL-6 signaling in vivo.

    Ben A Croker;Danielle L Krebs;Jian-Guo Zhang;Sam Wormald

  • The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

    András Kotschy;Zoltán Szlavik;James Murray;James Davidson

  • Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    Andrew W. Roberts;John F. Seymour;John F. Seymour;Jennifer R. Brown;William G. Wierda

  • Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

  • The genomic landscape of hypodiploid acute lymphoblastic leukemia

    Linda Holmfeldt;Lei Wei;Ernesto Diaz-Flores;Michael Walsh

  • Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Matthew S. Davids;Andrew W. Roberts;Andrew W. Roberts;John F. Seymour;John F. Seymour;John M. Pagel

  • Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl

    Warren S. Alexander;Andrew W. Roberts;Nicos A. Nicola;Ruili Li

  • Deficiency of the hematopoietic cell-specific Rho family GTPase Rac2 is characterized by abnormalities in neutrophil function and host defense.

    Andrew W. Roberts;Chaekyun Kim;Ling Zhen;John B. Lowe

  • RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis.

    James A Rickard;James A Rickard;Joanne A O'Donnell;Joanne A O'Donnell;Joseph M Evans;Joseph M Evans;Najoua Lalaoui;Najoua Lalaoui

  • Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

    Francesco Dieli;David Vermijlen;Fabio Fulfaro;Nadia Caccamo

  • Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.

    C. D. DiNardo;I. S. Tiong;I. S. Tiong;A. Quaglieri;S. MacRaild

  • Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure

    Andrew Spencer;H. Miles Prince;Andrew W. Roberts;Ian W. Prosser

  • Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin

    Shinya Kimura;Andrew W. Roberts;Donald Metcalf;Warren S. Alexander

  • G-CSF: A key regulator of neutrophil production, but that's not all!

    Andrew W. Roberts

  • Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

    Constantine S Tam;Mary Ann Anderson;Christiane Pott;Rishu Agarwal

  • AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.

    Sean Caenepeel;Sean P Brown;Brian Belmontes;Gordon Moody

Frequent Co-Authors

John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre
David C. S. Huang
David C. S. Huang Walter and Eliza Hall Institute of Medical Research
Constantine S. Tam
Constantine S. Tam University of Melbourne
Warren S. Alexander
Warren S. Alexander Walter and Eliza Hall Institute of Medical Research
David Ritchie
David Ritchie Peter MacCallum Cancer Centre
Andrew Wei
Andrew Wei Walter and Eliza Hall Institute of Medical Research
Jeff Szer
Jeff Szer Peter MacCallum Cancer Centre
Donald Metcalf
Donald Metcalf Walter and Eliza Hall Institute of Medical Research
Andrew Grigg
Andrew Grigg Austin Hospital
Andrew Spencer
Andrew Spencer Monash University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Aspiring medical professionals have more options than ever for advancing their education and expanding career opportunities. For those interested in specialized nursing roles, accelerated msn psychiatric np programs provide a fast track to becoming a psychiatric mental health nurse practitioner.

Beyond clinical roles, a career in healthcare administration is growing in demand. Students can explore online healthcare administration programs to gain key skills in management, policy, and leadership. For those looking for advanced credentials at an affordable price, there are also affordable online mha programs available to fit various budgets and schedules.

Experienced nurses seeking to elevate their clinical expertise and leadership capabilities may consider the best dnp programs online to earn a Doctor of Nursing Practice. These online pathways offer flexibility for working professionals while supporting career advancement in the evolving healthcare landscape.

Best Scientists Citing Andrew W. Roberts

Trending Scientists